2025 Q3 -tulosraportti
Vain PDF
76 päivää sitten
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
49
Myynti
Määrä
534
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 49 | NON | NON | ||
| 100 | NON | NON | ||
| 2 | NON | SSWM | ||
| 1 | AVA | SSWM | ||
| 114 | AVA | NON |
Ylin
25,2VWAP
Alin
23,5VaihtoMäärä
1,5 61 074
VWAP
Ylin
25,2Alin
23,5VaihtoMäärä
1,5 61 074
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 14 634 | 1 437 | +13 197 | 0 |
| SSW Market Making GmbH | 3 150 | 1 749 | +1 401 | 0 |
| Avanza Bank AB | 10 373 | 8 972 | +1 401 | 866 |
| Nordea Bank Abp | 1 162 | 562 | +600 | 0 |
| Carnegie Investment Bank AB | 13 | 0 | +13 | 0 |
| Swedbank AB | 301 | 633 | −332 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 31 441 | 47 721 | −16 280 | 26 373 |
| Swedbank AB | 301 | 633 | −332 | 0 |
| Carnegie Investment Bank AB | 13 | 0 | +13 | 0 |
| Nordea Bank Abp | 1 162 | 562 | +600 | 0 |
| SSW Market Making GmbH | 3 150 | 1 749 | +1 401 | 0 |
| Avanza Bank AB | 10 373 | 8 972 | +1 401 | 866 |
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 15.5.2025 | |
| 2024 Q4 -tulosraportti | 28.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5 t sittenHas anyone received any type of indication on the pricing of Cessatech products compared to competing products (and thereby potential margin development)? For me, this is absolutely crucial regarding growth and future potential profits (and thereby the value of the share). I asked the question at the previous online meeting with Cessatech but received no concrete answer (which in itself is understandable). Regardless, this is one of the most essential questions we have to justify the under/over valuation of the share.
·3 t sittenIt's the latest that has been found, could be more now could also be the same, nothing concrete announced. The only approved alternative is probably drops, which is cumbersome and requires more personnel but is slightly cheaper compared to sedare/ct001. The difference is quickly saved and more, as well as a better patient experience etc. An unknown for me is how much money is spent on staff training, given that they split the costs, I assume Cessatech also has to cover a bit here. But 15-20 dollars is probably not unlikely they can achieve, a bit what I have included in my analysis so far
·1 päivä sitten · MuokattuWhat is the expectation for the price of this stock? I can see it has moved nicely in the last months. Is it too late to jump in?
·1 päivä sittenBefore you ask, it is allowed to look through the last posts, then you will get a lot of good information :-)
·9 t sittenThanks for the answer! And great with such a positive experience, even though adults probably won't be the segment that is bet on. I was not at all aware they had the dental segment in mind already back then. Also a super way to become aware of the case and then earn money on it subsequently - free dentist and subsequent stock gain 😅
·1 päivä sittenCessatech has written to private investors that they expect to provide an update at the end of January. Ventis Pharma wrote this to an investor five days ago (excerpt from message): "The Sedare webstie build is complete and ready to go live. At this stage, the only remaining item is final product dating confirmation from our contract manufacturer, which is required to align with the commercial release. We expect this shortly and will provide an update as soon as timing is confirmed".
·1 päivä sittenGood to hear and thanks for spreading the information. It is of course as expected but still good to get confirmed that an administrative obstacle has not emerged from the FDA, which we haven't heard about before.
·2 päivää sittenWhat is YOUR estimate for the lowest price in 2026 (regardless of time or justification), assuming exclusively the "news" that we know today ? My own estimate is 15 DKK
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
76 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sittenHas anyone received any type of indication on the pricing of Cessatech products compared to competing products (and thereby potential margin development)? For me, this is absolutely crucial regarding growth and future potential profits (and thereby the value of the share). I asked the question at the previous online meeting with Cessatech but received no concrete answer (which in itself is understandable). Regardless, this is one of the most essential questions we have to justify the under/over valuation of the share.·3 t sittenIt's the latest that has been found, could be more now could also be the same, nothing concrete announced. The only approved alternative is probably drops, which is cumbersome and requires more personnel but is slightly cheaper compared to sedare/ct001. The difference is quickly saved and more, as well as a better patient experience etc. An unknown for me is how much money is spent on staff training, given that they split the costs, I assume Cessatech also has to cover a bit here. But 15-20 dollars is probably not unlikely they can achieve, a bit what I have included in my analysis so far
- ·1 päivä sitten · MuokattuWhat is the expectation for the price of this stock? I can see it has moved nicely in the last months. Is it too late to jump in?·1 päivä sittenBefore you ask, it is allowed to look through the last posts, then you will get a lot of good information :-)·9 t sittenThanks for the answer! And great with such a positive experience, even though adults probably won't be the segment that is bet on. I was not at all aware they had the dental segment in mind already back then. Also a super way to become aware of the case and then earn money on it subsequently - free dentist and subsequent stock gain 😅
- ·1 päivä sittenCessatech has written to private investors that they expect to provide an update at the end of January. Ventis Pharma wrote this to an investor five days ago (excerpt from message): "The Sedare webstie build is complete and ready to go live. At this stage, the only remaining item is final product dating confirmation from our contract manufacturer, which is required to align with the commercial release. We expect this shortly and will provide an update as soon as timing is confirmed".·1 päivä sittenGood to hear and thanks for spreading the information. It is of course as expected but still good to get confirmed that an administrative obstacle has not emerged from the FDA, which we haven't heard about before.
- ·2 päivää sittenWhat is YOUR estimate for the lowest price in 2026 (regardless of time or justification), assuming exclusively the "news" that we know today ? My own estimate is 15 DKK
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
49
Myynti
Määrä
534
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 49 | NON | NON | ||
| 100 | NON | NON | ||
| 2 | NON | SSWM | ||
| 1 | AVA | SSWM | ||
| 114 | AVA | NON |
Ylin
25,2VWAP
Alin
23,5VaihtoMäärä
1,5 61 074
VWAP
Ylin
25,2Alin
23,5VaihtoMäärä
1,5 61 074
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 14 634 | 1 437 | +13 197 | 0 |
| SSW Market Making GmbH | 3 150 | 1 749 | +1 401 | 0 |
| Avanza Bank AB | 10 373 | 8 972 | +1 401 | 866 |
| Nordea Bank Abp | 1 162 | 562 | +600 | 0 |
| Carnegie Investment Bank AB | 13 | 0 | +13 | 0 |
| Swedbank AB | 301 | 633 | −332 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 31 441 | 47 721 | −16 280 | 26 373 |
| Swedbank AB | 301 | 633 | −332 | 0 |
| Carnegie Investment Bank AB | 13 | 0 | +13 | 0 |
| Nordea Bank Abp | 1 162 | 562 | +600 | 0 |
| SSW Market Making GmbH | 3 150 | 1 749 | +1 401 | 0 |
| Avanza Bank AB | 10 373 | 8 972 | +1 401 | 866 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 15.5.2025 | |
| 2024 Q4 -tulosraportti | 28.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
76 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 15.5.2025 | |
| 2024 Q4 -tulosraportti | 28.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sittenHas anyone received any type of indication on the pricing of Cessatech products compared to competing products (and thereby potential margin development)? For me, this is absolutely crucial regarding growth and future potential profits (and thereby the value of the share). I asked the question at the previous online meeting with Cessatech but received no concrete answer (which in itself is understandable). Regardless, this is one of the most essential questions we have to justify the under/over valuation of the share.·3 t sittenIt's the latest that has been found, could be more now could also be the same, nothing concrete announced. The only approved alternative is probably drops, which is cumbersome and requires more personnel but is slightly cheaper compared to sedare/ct001. The difference is quickly saved and more, as well as a better patient experience etc. An unknown for me is how much money is spent on staff training, given that they split the costs, I assume Cessatech also has to cover a bit here. But 15-20 dollars is probably not unlikely they can achieve, a bit what I have included in my analysis so far
- ·1 päivä sitten · MuokattuWhat is the expectation for the price of this stock? I can see it has moved nicely in the last months. Is it too late to jump in?·1 päivä sittenBefore you ask, it is allowed to look through the last posts, then you will get a lot of good information :-)·9 t sittenThanks for the answer! And great with such a positive experience, even though adults probably won't be the segment that is bet on. I was not at all aware they had the dental segment in mind already back then. Also a super way to become aware of the case and then earn money on it subsequently - free dentist and subsequent stock gain 😅
- ·1 päivä sittenCessatech has written to private investors that they expect to provide an update at the end of January. Ventis Pharma wrote this to an investor five days ago (excerpt from message): "The Sedare webstie build is complete and ready to go live. At this stage, the only remaining item is final product dating confirmation from our contract manufacturer, which is required to align with the commercial release. We expect this shortly and will provide an update as soon as timing is confirmed".·1 päivä sittenGood to hear and thanks for spreading the information. It is of course as expected but still good to get confirmed that an administrative obstacle has not emerged from the FDA, which we haven't heard about before.
- ·2 päivää sittenWhat is YOUR estimate for the lowest price in 2026 (regardless of time or justification), assuming exclusively the "news" that we know today ? My own estimate is 15 DKK
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
49
Myynti
Määrä
534
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 49 | NON | NON | ||
| 100 | NON | NON | ||
| 2 | NON | SSWM | ||
| 1 | AVA | SSWM | ||
| 114 | AVA | NON |
Ylin
25,2VWAP
Alin
23,5VaihtoMäärä
1,5 61 074
VWAP
Ylin
25,2Alin
23,5VaihtoMäärä
1,5 61 074
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 14 634 | 1 437 | +13 197 | 0 |
| SSW Market Making GmbH | 3 150 | 1 749 | +1 401 | 0 |
| Avanza Bank AB | 10 373 | 8 972 | +1 401 | 866 |
| Nordea Bank Abp | 1 162 | 562 | +600 | 0 |
| Carnegie Investment Bank AB | 13 | 0 | +13 | 0 |
| Swedbank AB | 301 | 633 | −332 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 31 441 | 47 721 | −16 280 | 26 373 |
| Swedbank AB | 301 | 633 | −332 | 0 |
| Carnegie Investment Bank AB | 13 | 0 | +13 | 0 |
| Nordea Bank Abp | 1 162 | 562 | +600 | 0 |
| SSW Market Making GmbH | 3 150 | 1 749 | +1 401 | 0 |
| Avanza Bank AB | 10 373 | 8 972 | +1 401 | 866 |